Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7).
Many matrix metalloproteinases (MMPs) are tightly bound to tissues; matrilysin (MMP-7), although the smallest of the MMPs, is one of the most tightly bound. The most likely docking molecules for MMP-7 are heparan sulfate proteoglycans on or around epithelial cells and in the underlying basement membrane. This is established by extraction experiments and confocal microscopy. The enzyme is extracted from homogenates of postpartum rat uterus by heparin/heparan sulfate and by heparinase III treatment. The enzyme is colocalized with heparan sulfate in the apical region of uterine glandular epithelial cells and can be released by heparinase digestion. Heparan sulfate and MMP-7 are expressed at similar stages of the rat estrous cycle. The strength of heparin binding by recombinant rat proMMP-7 was examined by affinity chromatography, affinity coelectrophoresis, and homogeneous enzyme-based binding assay; the K(D) is 5-10 nM. Zymographic measurement of MMP-7 activity is greatly enhanced by heparin. Two putative heparin-binding peptides have been identified near the C- and N-terminal regions of proMMP-7; however, molecular modeling suggests a more extensive binding track or cradle crossing multiple peptide strands. Evidence is also found for the binding of MMP-2, -9, and -13. Binding of MMP-7 and other MMPs to heparan sulfate in the extracellular space could prevent loss of secreted enzyme, provide a reservoir of latent enzyme, and facilitate cellular sensing and regulation of enzyme levels. Binding to the cell surface could position the enzyme for directed proteolytic attack, for activation of or by other MMPs and for regulation of other cell surface proteins. Dislodging MMPs by treatment with compounds such as heparin might be beneficial in attenuating excessive tissue breakdown such as occurs in cancer metastasis, arthritis, and angiogenesis.
Yu
W H
WH
Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, Florida 33101, USA.
Woessner
J F
JF
D000818:Animals; D001665:Binding Sites; D002810:Chondroitinases and Chondroitin Lyases / Q000378:metabolism; D003196:Computer Graphics; D004706:Endodeoxyribonucleases / Q000037:antagonists & inhibitors; D004792:Enzyme Precursors / Q000737:chemistry; D004926:Escherichia coli; D005260:Female; D005455:Fluorescent Antibody Technique; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism*; D006493:Heparin / Q000378:metabolism; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D020783:Matrix Metalloproteinase 7 / Q000378:metabolism*; D008666:Metalloendopeptidases / Q000737:chemistry; D010446:Peptide Fragments / Q000276:immunology; D011133:Polysaccharide-Lyases / Q000378:metabolism; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D014599:Uterus / Q000378:metabolism
D002810:Chondroitinases and Chondroitin Lyases; D004706:Endodeoxyribonucleases; D004792:Enzyme Precursors; D019812:Heparan Sulfate Proteoglycans; D006493:Heparin; D006497:Heparan Sulfate; D020783:Matrix Metalloproteinase 7; D008666:Metalloendopeptidases; D010446:Peptide Fragments; D011133:Polysaccharide-Lyases; D011994:Recombinant Proteins; C019329:deoxyribonuclease II; C099583:promatrilysin; C021349:heparitinsulfate lyase